-
公开(公告)号:US20220139530A1
公开(公告)日:2022-05-05
申请号:US17594234
申请日:2020-04-21
发明人: Matthew KOLLADA , Humberto Andres GONZALEZ CABEZAS , Yuelu LIU , Monika Sharma MELLEM , Parvez AHAMMAD , Qingzhu GAO
IPC分类号: G16H30/20
摘要: The present disclosure provides systems and methods for automating the QC of MRI scans. Particularly, the inventors trained machine learning classifiers using features derived from brain MR images and associated processing to predict the quality of those images, which is based on the ground truth of an expert's opinion. In one example, classifiers that utilized features derived from preprocessing log files (textual files output during MRI preprocessing) were particularly accurate and demonstrated an ability to be generalized to new datasets, which allows the disclosed technology to be scalable to new datasets and MRI preprocessing pipelines.
-
公开(公告)号:US11289187B2
公开(公告)日:2022-03-29
申请号:US17270780
申请日:2019-08-29
发明人: Monika Sharma Mellem , Yuelu Liu , Parvez Ahammad , Humberto Andres Gonzalez Cabezas , Matthew Kollada
摘要: The method for evaluating mental health of a patient includes displaying a series of inquiries from mental health questionnaires on a display device. Each inquiry of the series of inquiries includes text and a set of answers. A series of selections is received from a user interface. Each selection of the series of selections is representative of an answer of the set of answers for each corresponding inquiry in the series of inquiries. Unprocessed MRI data are received. The unprocessed MRI data correspond to a set of MRI images of a biological structure associated with a patient. Using a machine learning model, the series of selections and the unprocessed MRI data are processed. The series of selections being processed corresponds to the series of inquiries. A symptom severity indicator for a mental health category of the patient is outputted.
-
3.
公开(公告)号:US11244762B2
公开(公告)日:2022-02-08
申请号:US17270730
申请日:2019-08-29
发明人: Yuelu Liu , Monika Sharma Mellem , Parvez Ahammad , Humberto Andres Gonzalez Cabezas , Matthew Kollada
IPC分类号: G16H50/20 , G16H30/20 , G16H30/40 , G16H50/70 , G16H10/20 , G16H50/30 , G16H20/70 , G06N20/00 , G06K9/62 , A61B5/16 , A61B5/00 , A61B5/055
摘要: A system for evaluating mental health of patients includes a memory and a control system. The memory contains executable code storing instructions for performing a method. The control system is coupled to the memory and includes one or more processors. The control system is configured to execute the machine executable code to cause the control system to perform the method: A selection of answers associated with a patient is received. The selection of answers corresponds to each question in a series of questions from mental health questionnaires. Unprocessed MRI data are received. The unprocessed MRI data correspond to a set of MRI images of a biological structure associated with the patient. The unprocessed MRI data is processed to output a set of MRI features. Using a machine learning model, the selection of answers and the set of MRI features are processed to output a mental health indication of the patient.
-
公开(公告)号:US10950327B2
公开(公告)日:2021-03-16
申请号:US16295374
申请日:2019-03-07
摘要: The present tools and methods for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject. These tools and methods relates to a genotype and neurophenotype topography-based approach for analyzing brain neuroimaging and gene expression maps to identify drug targets associated with neurobehavioral phenotypes and, conversely, neurobehavioral phenotypes associated with potential drug targets, to develop rational design and application of pharmacological therapeutics for brain disorders, and to provide methods and tools for treatment of subjects in need of neurological therapy.
-
公开(公告)号:US10538530B2
公开(公告)日:2020-01-21
申请号:US16122780
申请日:2018-09-05
发明人: Robert M. Jones , Mariangela Urbano , Gary Brandt , Mark Chambers , David Hardick , Chris Knight , Jason Tierney , Chris Lock
IPC分类号: C07D487/10 , A61P25/20 , A61P25/22 , A61P25/18 , A61P25/24
摘要: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
-
公开(公告)号:US20230084719A1
公开(公告)日:2023-03-16
申请号:US17311974
申请日:2019-12-12
发明人: Gary Brandt
IPC分类号: C07D519/00 , A61P25/22
摘要: The present invention relates to 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds of Formula (I): wherein A, B, G, R1, R1b, R1C, R2 and X are as defined herein. The present compounds are vasopressin receptor antagonists (in particular of the Via receptor) for the treatment of neuro-psychological disorders, such as e.g. autism, anxiety, stress-related disorders, depression, schizophrenia or bipolar disorder. The present description discloses the synthesis of exemplary compounds, as well as pharmacological data thereof (e.g. pages 71 to 246; examples 1 to 49; tables 1 to 5). An exemplary compound is e.g. 8-chloro-1-(2-(5-fluoropyridin-2-yl)-2,6-diazaspiro[3.3]heptan-6-yl)-5-methyl-5,6-dihydro-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine (example 1, compound no. 1).
-
公开(公告)号:US20220162202A1
公开(公告)日:2022-05-26
申请号:US17390531
申请日:2021-07-30
发明人: Edward Roberts , Miguel A. Guerrero , Mariangela Urbano , Hugh Rosen , Robert M. Jones , Candace Mae Laxamana , Xianrui Zhao , Eric Douglas Turtle
IPC分类号: C07D413/14 , A61P25/00 , A61P25/06
摘要: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof. wherein X, Y, R1, R2, R4, R5, R6, R7, R8 and R11 are as defined herein.
-
公开(公告)号:US20210361210A1
公开(公告)日:2021-11-25
申请号:US17443387
申请日:2021-07-26
摘要: A system includes a display device, a user interface, a memory, and a control system. The memory contains machine readable medium including machine executable code storing instructions for performing a method. The control system is coupled to the memory, and includes one or more processors. The control system is configured to execute the machine executable code to cause the control system to display, on the display device, a series of questions from mental health questionnaires. The series of questions includes text and answers for each question. From the user interface, a selection of answers of each of the displayed series of questions is received from a patient. Using a Bayesian Decision List, the received selection of answers is processed to output an indication of mental health of the patient. The indication of mental health identifies a kappa opioid receptor antagonist to which the patient would likely be a higher responder.
-
公开(公告)号:US11124504B2
公开(公告)日:2021-09-21
申请号:US16846136
申请日:2020-04-10
发明人: Edward Roberts , Miguel A. Guerrero , Mariangela Urbano , Hugh Rosen , Robert M. Jones , Candace Mae Laxamana , Xianrui Zhao , Eric Douglas Turtle
IPC分类号: C07D413/14 , A61P25/00 , A61P25/06
摘要: Compounds are provided that antagonize the kappa-opioid receptor (KOR) and products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof: wherein X, Y, R1, R2, R4, R5 R6, R7, R8 and R11 are as defined herein.
-
10.
公开(公告)号:US20190272889A1
公开(公告)日:2019-09-05
申请号:US16295374
申请日:2019-03-07
摘要: The present tools and methods for detecting, diagnosing, predicting, prognosticating, or treating a neurobehavioral phenotype in a subject. These tools and methods relates to a genotype and neurophenotype topography-based approach for analyzing brain neuroimaging and gene expression maps to identify drug targets associated with neurobehavioral phenotypes and, conversely, neurobehavioral phenotypes associated with potential drug targets, to develop rational design and application of pharmacological therapeutics for brain disorders, and to provide methods and tools for treatment of subjects in need of neurological therapy.
-
-
-
-
-
-
-
-
-